These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 29336436)

  • 21. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment.
    Carr SS; Hooper AJ; Sullivan DR; Burnett JR
    Pathology; 2019 Feb; 51(2):148-154. PubMed ID: 30595507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Reasons for a combination].
    Núñez-Cortés JM
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():40-1. PubMed ID: 25043547
    [No Abstract]   [Full Text] [Related]  

  • 24. News from ESC congress 2019: New ESC/EAS guidelines for dyslipidaemia management published.
    Stock J
    Atherosclerosis; 2019 Dec; 291():124-126. PubMed ID: 31668350
    [No Abstract]   [Full Text] [Related]  

  • 25. High-intensity lipid-lowering regimens in patients with stable coronary artery disease: the intriguing question of all-cause mortality.
    Danchin N; Simon T
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):328-330. PubMed ID: 31539045
    [No Abstract]   [Full Text] [Related]  

  • 26. New joint consensus initiative on quantifying atherogenic lipoproteins.
    Stock JK
    Atherosclerosis; 2018 Dec; 279():97-99. PubMed ID: 30318139
    [No Abstract]   [Full Text] [Related]  

  • 27. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atherogenic dyslipidemia.
    Hayden MR
    J Cardiometab Syndr; 2006; 1(3):166-7. PubMed ID: 17679821
    [No Abstract]   [Full Text] [Related]  

  • 29. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.
    Jialal I; Smith G
    Metab Syndr Relat Disord; 2012 Jun; 10(3):159-60. PubMed ID: 22568574
    [No Abstract]   [Full Text] [Related]  

  • 30. Glucose and LDL lowering: the need for intensive therapy.
    Del Prato S
    Curr Vasc Pharmacol; 2012 Nov; 10(6):687-9. PubMed ID: 23259554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ApoB.
    Sniderman AD; Pencina M; Thanassoulis G
    Circ Res; 2019 May; 124(10):1425-1427. PubMed ID: 31070997
    [No Abstract]   [Full Text] [Related]  

  • 32. Lipids and antithrombotic treatment.
    Agewall S
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):71. PubMed ID: 32176294
    [No Abstract]   [Full Text] [Related]  

  • 33. Lipid-lowering nutraceuticals update on scientific evidence.
    Derosa G; Colletti A; Maffioli P; D'Angelo A; Lupi A; Zito GB; Mureddu GF; Raddino R; Fedele F; Cicero AFG
    J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):845-859. PubMed ID: 32639326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New trials in the scene of cardiovascular disease: innovation, controversy, and reassurance.
    Badimon L
    Cardiovasc Res; 2021 Mar; 117(4):e52-e54. PubMed ID: 33615348
    [No Abstract]   [Full Text] [Related]  

  • 35. The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease.
    Windler E; Schöffauer M; Zyriax BC
    Diab Vasc Dis Res; 2007 Jun; 4(2):136-42. PubMed ID: 17654448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipid Lowering Therapy for Atherosclerotic Cardiovascular Disease: It Is Not So Simple.
    Vincent J
    Clin Pharmacol Ther; 2018 Aug; 104(2):220-224. PubMed ID: 30117592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increasing HDL-cholesterol and prevention of atherosclerosis: A critical perspective.
    Parhofer KG
    Atheroscler Suppl; 2015 May; 18():109-11. PubMed ID: 25936313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacology of Nutraceuticals with Lipid Lowering Properties.
    Poli A; Visioli F
    High Blood Press Cardiovasc Prev; 2019 Apr; 26(2):113-118. PubMed ID: 30877602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on strategies to increase HDL quantity and function.
    Duffy D; Rader DJ
    Nat Rev Cardiol; 2009 Jul; 6(7):455-63. PubMed ID: 19488077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials.
    Drexel H; Rosano GMC; Lewis BS; Huber K; Vonbank A; Dopheide JF; Mader A; Niessner A; Savarese G; Wassmann S; Agewall S
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):97-103. PubMed ID: 31298686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.